The checkpoint kinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
2010

CHK2 1100delC Mutation and Head and Neck Cancer

Sample size: 91 publication Evidence: low

Author Information

Author(s): Scheckenbach Kathrin, Papadopoulou Galatia, Hoffmann Thomas K, Chaker Adam, Bier Henning, Schipper Jörg, Balz Vera, Wagenmann Martin

Primary Institution: Heinrich-Heine-University Düsseldorf

Hypothesis

Does the CHK2 1100delC germ line mutation contribute to the development of squamous cell carcinoma of the head and neck?

Conclusion

The CHK2 1100delC variant does not appear to significantly influence the risk of developing squamous cell carcinoma of the head and neck.

Supporting Evidence

  • None of the 91 patients with SCCHN carried the CHK2 1100delC variant.
  • The incidence of the 1100delC variant in the Northrhine-Westphalia population is reported to be 0.9%.
  • The study included patients with various tumor sites and stages.

Takeaway

The study looked at 91 patients with head and neck cancer and found that none had a specific gene mutation that was thought to increase cancer risk.

Methodology

Direct sequence analysis was performed on blood samples from 91 patients to check for the CHK2 1100delC mutation.

Limitations

The study had a relatively small sample size of 91 patients.

Participant Demographics

The study included 91 patients, 15 women and 76 men, aged 32 to 82 years, with a mean age of 56 years.

Digital Object Identifier (DOI)

10.1186/1477-5751-9-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication